Lantheus Holdings, Inc. (LNTH)
NASDAQ
Closed
Aug 24, 2026
Day's Range
100.0752 wk Range
49.67Overview - LNTH - Lantheus Holdings, Inc.
Key Statistics
Valuation
Enterprise Value
6.55B
P/E (Trailing)
‪23.91‬
P/E (Forward)
‪15.80‬
PEG Ratio
‪15.80‬
Price / Sales (TTM)
‪4.19‬
Price / Book
‪4.97‬
EV / EBITDA
‪16.71‬
Profitability
Gross Margin
‪62.30%‬
Profit Margin
‪17.69%‬
Operating Margin
‪25.81%‬
Return on Assets
‪8.37%‬
Return on Equity
‪22.21%‬
Ownership
Shares Outstanding
65.26M
Float
58.49M
Short % of Shares Outstanding
‪12.85%‬
Held by Insiders
‪2.07%‬
Held by Institutions
‪117.16%‬
Price stats
Beta
‪-0.03‬
50-Day Avg
‪103.98‬
200-Day Avg
‪81.86‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
11 analysts
Average price target
‪$ 107.04‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - LNTH - Lantheus Holdings, Inc.
Peers - LNTH - Lantheus Holdings, Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
Profile Summary - LNTH - Lantheus Holdings, Inc.
About
Lantheus Holdings, Inc. is a leading radiopharmaceutical-focused company that develops, manufactures, and commercializes diagnostic and therapeutic products to assist clinicians in diagnosing and treating heart disease, cancer, and other conditions worldwide. Its portfolio includes DEFINITY, an injectable ultrasound…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
